{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Luoma AM"],"funding":["NCI NIH HHS"],"pagination":["2918-2935.e29"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9508682"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["185(16)"],"pubmed_abstract":["Neoadjuvant immune checkpoint blockade has shown promising clinical activity. Here, we characterized early kinetics in tumor-infiltrating and circulating immune cells in oral cancer patients treated with neoadjuvant anti-PD-1 or anti-PD-1/CTLA-4 in a clinical trial (NCT02919683). Tumor-infiltrating CD8 T cells that clonally expanded during immunotherapy expressed elevated tissue-resident memory and cytotoxicity programs, which were already active prior to therapy, supporting the capacity for rapid response. Systematic target discovery revealed that treatment-expanded tumor T cell clones in responding patients recognized several self-antigens, including the cancer-specific antigen MAGEA1. Treatment also induced a systemic immune response characterized by expansion of activated T cells enric"],"journal":["Cell"],"pubmed_title":["Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy."],"pmcid":["PMC9508682"],"funding_grant_id":["T32 CA207021","R01 CA173750","R01 CA238039","R01 CA234018","R01 CA251599"],"pubmed_authors":["Rozenblatt-Rosen O","Gurer C","Ashenberg O","Schoenfeld JD","Suo S","Ferretti AP","Gunasti L","MacBeath G","Haddad RI","Wucherpfennig KW","Nabilsi N","Regev A","Dionne D","Tadros J","Van Allen EM","Ricker CA","Luoma AM","Chen YH","Uppaluri R","Porter CBM","Liao S","Criscitiello S","Wang Y"],"additional_accession":[]},"is_claimable":false,"name":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.","description":"Neoadjuvant immune checkpoint blockade has shown promising clinical activity. Here, we characterized early kinetics in tumor-infiltrating and circulating immune cells in oral cancer patients treated with neoadjuvant anti-PD-1 or anti-PD-1/CTLA-4 in a clinical trial (NCT02919683). Tumor-infiltrating CD8 T cells that clonally expanded during immunotherapy expressed elevated tissue-resident memory and cytotoxicity programs, which were already active prior to therapy, supporting the capacity for rapid response. Systematic target discovery revealed that treatment-expanded tumor T cell clones in responding patients recognized several self-antigens, including the cancer-specific antigen MAGEA1. Treatment also induced a systemic immune response characterized by expansion of activated T cells enric","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-04T20:28:42.114Z","creation":"2025-04-04T20:28:42.114Z"},"accession":"S-EPMC9508682","cross_references":{"pubmed":["35803260"],"doi":["10.1016/j.cell.2022.06.018"]}}